Why did Cara Therapeutics stock crash 43% Thursday?
Apr 29, 2021 · Shares of Cara Therapeutics ( CARA -0.87% ) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral...
Where can I buy shares of Cara?
$13.07 Price as of April 20, 2022, 8:00 p.m. ET Investors head for the exits following a major clinical setback. What happened Shares of Cara Therapeutics ( CARA -0.53% ), …
What is the upside for Cara Therapeutics'stock?
Apr 29, 2021 · The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis. So what With the...
What are analysts'target prices for Cara Therapeutics stock?
Dec 05, 2019 · Cara Therapeutics stock (NASDAQ:CARA) fell by 27.8% less than on Tuesday. The decline came after the pharmacist announced the results of a phase 2 clinical trial that evaluated oral Korsuva in the treatment of patients with chronic kidney disease (CKD) with moderate to severe (itching) itching.
Why is Cara dropping?
Will Cara stock go up?
Is Cara a good buy?
Where is Cara Therapeutics located?
What does Cara Therapeutics do?
How many employees does Cara have?
Investors head for the exits following a major clinical setback
What happened
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
So what
Shares of Cara Therapeutics ( NASDAQ:CARA), a clinical-stage biotech, dropped by as much as 28.1% in after-hours trading Thursday, and remain more than 25% lower in pre-market trading Friday morning.
Now what
Cara was hoping that CR845 would transform into a disruptive new pain medicine capable of displacing problematic opioids such as morphine or hydrocodone. These weak midstage results, however, suggest that this possibility is now off the table.
What happened
The good news is that CR845's IV formulation for post-operative pain and its chronic kidney disease-associated pruritis (itching) treatment remain very much in play at this point.
So what
Shares of Cara Therapeutics (NASDAQ: CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
Now what
With the biotech stock falling so heavily today, you'd think that all the results from the phase 2 trial were really bad. That wasn't entirely the case, though.
Who sold Cara Therapeutics stock?
Despite the bad news, Cara Therapeutics doesn't think it's the end of the road for oral Korsuva in treating atopic dermatitis. Chief Medical Officer Joana Goncalves said, "We now have a defined patient group and active dose range for Oral KORUSVA in which to design a registration program that we expect to discuss with the FDA in the coming months."
What is the NASDAQ symbol for Cara Therapeutics?
Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.
How much does Cara Therapeutics make?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
What is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $597.60 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.18 on an earnings per share basis.
What is the official website of Cara Therapeutics?
is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
When will Cara Therapeutics release its earnings?
The official website for Cara Therapeutics is www.caratherapeutics.com.
Is Cara Therapeutics a buy?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Cara Therapeutics.
